The Diagnostic Delay Gap: What Traditional Research Misses About Endometriosis

Executive Introduction

One of the most persistent challenges in endometriosis care is the diagnostic delay gap. Despite advances in imaging, surgical techniques, and clinical awareness, many women continue to experience years between symptom onset and diagnosis. Understanding the diagnostic delay gap in endometriosis requires looking beyond traditional clinical research and examining how patients navigate real-world healthcare pathways.

This delay is measurable, consequential, and potentially modifiable.

Systematic reviews and international studies have reported average diagnostic delays of approximately 6 to 10 years, with variation according to country, healthcare system, population studied, and definition of delay. The interval may include several distinct stages: time from symptom onset to first consultation, time from first consultation to specialist referral, time from specialist evaluation to diagnostic confirmation, and time from diagnosis to appropriate treatment.

This matters because diagnostic delay is not merely a waiting period. It is part of the disease burden.

Before diagnosis, many patients may experience repeated consultations, fragmented referrals, inconclusive investigations, empirical treatments, emergency visits, school or work impairment, psychological distress, and progressive loss of trust in healthcare systems.

Traditional clinical research has contributed substantially to understanding the efficacy and safety of treatments for endometriosis. However, it often does not capture what happens before diagnosis: how symptoms are normalized, how patients navigate primary care and specialty care, where referral pathways fail, and how social, cultural, and system-level factors delay recognition.

This is the diagnostic delay gap.

It is the distance between biomedical knowledge about endometriosis and the real-world ability of healthcare systems to recognize the condition early enough to alter the patient journey.

The Burden Begins Before Diagnosis

Endometriosis affects an estimated 10% of women of reproductive age worldwide. It may present with dysmenorrhea, chronic pelvic pain, dyspareunia, infertility, fatigue, gastrointestinal symptoms, urinary symptoms, and impaired quality of life.

However, the burden often begins long before the disease is formally diagnosed.

The initial presentation is frequently fragmented. A patient may first report menstrual pain in adolescence, bowel symptoms in primary care, infertility in reproductive medicine, urinary complaints in urology, or chronic pain in emergency services. These encounters may occur over years and across different healthcare settings.

This creates a structural challenge.

Endometriosis does not always enter the healthcare system through one clear diagnostic pathway. It often appears through multiple partial signals distributed across gynecology, primary care, gastroenterology, urology, fertility medicine, emergency care, and mental health.

If the health system is not designed to connect these signals, diagnostic responsibility becomes dispersed. The patient may become the only continuous link between isolated clinical encounters.

In Brazil, this issue is especially relevant in the context of primary care and the SUS. Many women first seek care through primary healthcare services, where menstrual pain, pelvic pain, and nonspecific abdominal symptoms may be managed symptomatically before referral to specialized gynecological care. Barriers such as limited consultation time, unequal access to specialized imaging, regional disparities, low health literacy, and normalization of dysmenorrhea may amplify delays.

For this reason, diagnostic delay should not be interpreted only as an individual clinical failure. It should be analyzed as a healthcare delivery problem.

What Traditional Research Captures Well

Randomized controlled trials remain essential for evidence-based medicine. They provide high internal validity and are fundamental for assessing treatment efficacy, safety, and comparative benefit.

They help answer questions such as:

• Does a therapy reduce pain?
• Is an intervention safe?
• How does one treatment compare with another?
• What is the magnitude of benefit in a selected population?
• Which adverse events are associated with treatment?

This evidence is indispensable.

However, randomized trials are optimized to answer questions about interventions under controlled conditions. They are less suited to explaining the real-world pathway that precedes diagnosis and treatment.

In endometriosis, this distinction is critical.

A trial may tell us whether a treatment works after the patient has entered the correct diagnostic and therapeutic pathway. It usually does not tell us why entering that pathway took several years.

What Traditional Research Often Misses

Many of the most important unanswered questions in endometriosis are not purely pharmacological. They are operational, behavioral, and systemic.

They include:

• What is the average time from symptom onset to first healthcare contact?
• What is the average time from first healthcare contact to diagnostic confirmation?
• How many healthcare professionals are consulted before diagnosis?
• Which symptoms are most often underestimated or misattributed?
• Which specialties are involved before gynecological referral?
• What proportion of patients receive repeated symptomatic treatment without etiological investigation?
• Which socioeconomic, geographic, age-related, or cultural factors increase risk of delay?
• How does diagnostic uncertainty affect adherence, trust, and future healthcare-seeking behavior?

These questions map to measurable constructs in patient journey research.

They can be structured as:

• delay intervals;
• number of healthcare encounters;
• number and type of specialties consulted;
• diagnostic tests performed;
• referral sequence;
• symptom clusters;
• patient-reported burden;
• treatment attempts before diagnosis;
• healthcare utilization before diagnosis;
• work and education impact;
• barriers to access.

Traditional research often abstracts away these pathway variables. Yet these variables determine whether patients reach diagnosis and treatment in time.

The Diagnostic Delay Gap: Definition and Measurement

The diagnostic delay gap can be defined as the measurable difference between expected timely recognition of endometriosis and the actual real-world interval experienced by patients between symptom onset and diagnosis.

It can be decomposed into at least four intervals:

1. Patient interval: time from symptom onset to first healthcare consultation.
2. Primary care interval: time from first consultation to suspicion of endometriosis or referral.
3. Specialist interval: time from referral to gynecological evaluation, imaging, or diagnostic confirmation.
4. Treatment interval: time from diagnosis to appropriate therapeutic planning.

This framework matters because “diagnostic delay” is often reported as a single number. In practice, it is a sequence of delays produced by different mechanisms.

Some delays may reflect symptom normalization. Others may reflect access barriers, lack of specialist referral, inadequate imaging pathways, fragmented records, or insufficient longitudinal symptom tracking.

Without decomposing the delay, it is difficult to design effective interventions.

A digital health intervention, for example, may reduce the patient interval through education, but fail to reduce the specialist interval if referral access remains limited. A professional education program may improve suspicion in primary care, but fail if there is no clear diagnostic pathway.

Therefore, the diagnostic delay gap should be treated as a measurable implementation problem, not only as a descriptive epidemiological finding.

Why Patient Journey Data Matters

Patient journey research changes the central question.

Instead of asking only, “What treatment works?”, it asks:

What happens to the patient before treatment becomes possible?

For endometriosis, patient journey data can capture:

• age at symptom onset;
• first symptom reported;
• time to first consultation;
• first point of care;
• number of consultations before diagnosis;
• specialties consulted;
• imaging and laboratory tests performed;
• prior diagnoses received;
• empirical treatments attempted;
• emergency visits;
• work or school absenteeism;
• impact on quality of life;
• health literacy and educational needs;
• barriers to specialized care.

This type of evidence transforms individual narratives into structured data. Once the pathway is measured, it becomes possible to identify bottlenecks, compare subgroups, evaluate interventions, and monitor improvement over time.

For Medical Affairs, HEOR, policy, and digital health teams, patient journey evidence is valuable because it links clinical burden to healthcare utilization, unmet needs, access barriers, and implementation opportunities.

Real-World Evidence as a Necessary Complement

Real-World Evidence should not be used to replace randomized trials. It should be used to answer questions that randomized trials are not designed to answer.

In endometriosis, many relevant questions occur outside trial settings and before formal diagnosis.

Real-world data sources may include:

• electronic health records;
• claims databases;
• registries;
• patient-reported outcomes;
• structured surveys;
• digital health platforms;
• symptom trackers;
• longitudinal patient journey assessments.

When analyzed rigorously, these sources can help answer:

• where diagnostic delay occurs;
• which patient groups experience longer delays;
• which symptom clusters are associated with higher diagnostic risk;
• what healthcare utilization occurs before diagnosis;
• how treatment patterns evolve after diagnosis;
• which interventions shorten the diagnostic pathway.

However, RWE requires methodological caution.

Observational data are vulnerable to selection bias, confounding, missing data, misclassification, recall bias, and measurement error. Patient-generated data may overrepresent digitally engaged populations and underrepresent patients with lower literacy, limited internet access, or reduced access to health services.

Therefore, credible RWE requires transparent protocols, predefined outcomes, validated instruments when available, data quality monitoring, appropriate analytical methods, and explicit discussion of limitations.

Digital Health as Evidence Infrastructure

Digital health should not be reduced to apps, reminders, or educational content.

In women’s health, its more strategic role may be to create structured evidence from fragmented patient experiences.

A scientifically designed platform can support:

• symptom tracking;
• patient-reported outcome collection;
• longitudinal monitoring;
• educational modules;
• care navigation;
• engagement analytics;
• structured patient journey mapping.

This creates a dual function.

The platform supports the patient while generating real-world data.

But this only works if evidence generation is built into the platform design from the beginning. Data collection must be structured. Consent must be explicit. Outcomes must be clinically meaningful. Privacy must be protected. Bias must be monitored. Governance must be auditable. The system must comply with applicable data protection rules, including LGPD in Brazil.

Digital health also introduces risks.

These include digital exclusion, low engagement, self-report bias, incomplete follow-up, variable data quality, and the possibility that digitally active users differ systematically from the broader patient population.

If these risks are ignored, digital platforms may produce attractive dashboards but weak evidence.

The goal should be different: digital health as a learning system capable of supporting care while generating methodologically credible patient-centered evidence.

EndoConnect as a Practical Example

EndoConnect was developed as a digital health initiative focused on education, navigation, and support for women affected by endometriosis.

Its broader potential lies in connecting patient education with structured evidence generation.

In a patient journey and RWE framework, EndoConnect could support data collection on:

• age at symptom onset;
• time from symptom onset to first consultation;
• time from first consultation to diagnosis;
• number of healthcare professionals consulted;
• symptom clusters;
• previous diagnoses;
• previous treatments;
• imaging access;
• emergency visits;
• work and education impact;
• patient-reported outcomes;
• perceived educational needs;
• engagement with digital content;
• usability and acceptability.

This framework is directly relevant to implementation in primary care and public health contexts. In SUS/APS settings, a digital platform may help identify educational gaps, support earlier suspicion, organize symptom information, and generate data on barriers to access.

Evaluation should include not only usability metrics, such as SUS and TAM, but also implementation outcomes such as acceptability, adoption, feasibility, engagement, equity, data completeness, and potential integration into care pathways.

The strategic point is not that one platform solves diagnostic delay.

It does not.

The point is that digital health initiatives in endometriosis should be designed as evidence-capable systems. If they only distribute information, their impact will remain limited. If they generate structured patient journey data, they can contribute to research, implementation, policy, and better decision-making.

Implications for Stakeholders

The diagnostic delay gap has implications for multiple stakeholders.

For Medical Affairs, it reframes unmet need. The unmet need is not only better treatment, but earlier recognition, better navigation, and better evidence regarding the pre-diagnostic period.

For RWE and HEOR teams, diagnostic delay can be studied as a burden-of-disease and healthcare-utilization problem, with implications for costs, productivity, quality of life, and value demonstration.

For health systems, measuring delay can help identify bottlenecks in primary care, referral networks, imaging access, and specialist evaluation.

For policymakers, patient journey evidence can support pathway redesign, professional education, and prioritization of women’s health.

For digital health innovators, the standard should be higher than engagement. Platforms should demonstrate evidence value, data quality, equity, and implementation feasibility.

For patients, earlier recognition can reduce uncertainty and support better navigation through care.

Endometriosis therefore becomes more than a gynecological disease. It becomes a test case for whether healthcare systems can identify complex women’s health conditions before years of avoidable burden accumulate.

Research and Implementation Priorities

Future work should move from general statements about diagnostic delay to structured measurement.

Priority areas include:

• standardized definitions of diagnostic delay in endometriosis;
• decomposition of delay into patient, primary care, specialist, and treatment intervals;
• patient journey studies in public and private healthcare systems;
• evaluation of diagnostic delay in adolescents and underserved populations;
• integration of patient-reported outcomes into digital platforms;
• assessment of healthcare utilization before diagnosis;
• studies on work, education, and productivity impact;
• evaluation of digital tools for symptom organization and care navigation;
• governance frameworks for patient-generated data;
• implementation studies in primary care and SUS contexts.

The goal is not to replace randomized controlled trials.

The goal is to complement them with evidence that reflects the complexity of real care.

Conclusion

The greatest gap in endometriosis may not be the absence of clinical knowledge.

It may be the failure to translate that knowledge into earlier recognition in real-world healthcare pathways.

Randomized trials remain essential for evaluating treatments. But they cannot fully explain why patients spend years before reaching the point where treatment decisions can even begin.

Closing the diagnostic delay gap requires a broader evidence model.

It requires patient journey research.

It requires Real-World Evidence.

It requires digital platforms capable of generating structured, ethical, and clinically meaningful data.

Above all, it requires healthcare systems to stop treating diagnostic delay as an unfortunate background feature of endometriosis and start treating it as a measurable, modifiable outcome.

Better treatments matter.

But for many women, the first unmet need is more basic:

to be recognized sooner.